Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study.
暂无分享,去创建一个
J. Baselga | R. Herbst | C. Saura | M. Marotti | J. Tessier | J. D. Del Campo | B. Collins | J. Heymach